425: Cyclo Therapeutics Secures $2 Million Convertible Note from Rafael Holdings

Cyclo Therapeutics has entered into a Note Purchase Agreement with Rafael Holdings, issuing a $2 million convertible promissory note to bolster working capital.

Summary

• Cyclo Therapeutics, Inc. secured a $2 million convertible promissory note from Rafael Holdings, Inc. on June 11, 2024.
• Rafael Holdings, already holding approximately 31.5% of Cyclo Therapeutics' outstanding common stock, is the note purchaser.
• The note matures on November 11, 2024, and carries an interest rate of 5% per annum, payable upon maturity.
• Cyclo Therapeutics has the option to prepay the note in full at any time.
• Rafael Holdings has the option to convert the principal amount of the note into shares of common stock under certain conditions.
• Conversion is automatic if Cyclo Therapeutics enters into a Qualified Financing (gross proceeds of at least $8 million, excluding this note).
• Conversion is also at Rafael's option if a Sale Transaction occurs before repayment.
• The conversion price will be the lesser of $0.95 or 80% of the purchase price in the Qualified Financing or the implied value in the Sale Transaction.
• An Event of Default, including failure to pay principal or interest, could lead to acceleration of the obligations under the note.
• Cyclo Therapeutics intends to use the proceeds for working capital and general corporate purposes.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. Securing funding is generally positive, but the debt obligation and potential dilution temper the outlook.

Positives

• Cyclo Therapeutics secures $2 million in funding to support working capital and general corporate purposes.
• The note can be prepaid by the company at any time, providing flexibility.
• The conversion feature could potentially reduce debt if Rafael Holdings exercises its conversion rights.

Negatives

• The note accrues interest at 5% per annum, increasing the company's financial obligations.
• Failure to meet payment obligations constitutes an Event of Default, potentially leading to accelerated repayment.
• The conversion of the note could dilute existing shareholders' equity.

Risks

• Failure to repay the principal or interest on time constitutes an Event of Default, potentially leading to acceleration of the debt.
• The conversion of the note could dilute existing shareholders' equity.
• The company's ability to secure a Qualified Financing or avoid a Sale Transaction on unfavorable terms could impact the conversion terms.
• The company's reliance on Rafael Holdings for funding could create a dependency.

Future Outlook

Cyclo Therapeutics intends to use the proceeds from the note for working capital and general corporate purposes, suggesting a focus on sustaining and growing its operations.

Management Comments

• There are no direct management quotes in the document, but the company's actions indicate a strategic move to secure additional funding.

Industry Context

This announcement reflects a common financing strategy for small-cap biotech companies, utilizing convertible notes to secure funding while offering potential upside to investors through equity conversion. The involvement of a major shareholder like Rafael Holdings demonstrates confidence in the company's prospects.

Comparison to Industry Standards

• Convertible notes are a fairly standard financing tool for companies of this size, especially in the biotech sector.
• The 5% interest rate is within the typical range for such notes, although it can vary based on the company's risk profile and market conditions.
• The conversion terms, including the $0.95 base price and 80% discount on Qualified Financing, are designed to incentivize conversion while providing downside protection to the investor.
• Similar companies like Aeterna Zentaris or Cassava Sciences have used convertible notes to fund operations and clinical trials.

Related Party Transactions

• The transaction involves Rafael Holdings, a major shareholder (31.5%), indicating a related-party transaction.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into common stock.
• Employees benefit from the company's increased financial stability.
• Customers and suppliers can expect continued operations and service.

Next Steps

• Cyclo Therapeutics will utilize the $2 million for working capital and general corporate purposes.
• Rafael Holdings will monitor the company's performance and consider conversion options.
• The company may pursue a Qualified Financing or Sale Transaction, which would trigger conversion of the note.

Key Dates